Shanghai Aladdin Biochemical Technology Co.Ltd(688179)
Independent opinions of independent directors on matters related to the 23rd Meeting of the third board of directors Shanghai Aladdin Biochemical Technology Co.Ltd(688179) (hereinafter referred to as “the company”) the 23rd Meeting of the third board of directors was held on March 10, 2022 by on-site combined with communication. In accordance with the company law of the people’s Republic of China (hereinafter referred to as “the company law”) The relevant provisions of laws, regulations and rules and regulations such as the Listing Rules of Shanghai Stock Exchange science and Innovation Board (revised in December 2020) (hereinafter referred to as the “Listing Rules”), the Shanghai Aladdin Biochemical Technology Co.Ltd(688179) articles of Association (hereinafter referred to as the “articles of association”), the Shanghai Aladdin Biochemical Technology Co.Ltd(688179) independent director working system and so on, as the independent director of the company, We hereby express the following independent opinions on the following proposals considered at the 23rd Meeting of the third board of directors of the company: first, consider the proposal on further clarifying the specific plan for the company to issue convertible corporate bonds to unspecified objects
1. After review, the specific plan for the company to issue convertible corporate bonds to unspecified objects this time is that the board of directors of the company further defines the specific plan for issuing convertible corporate bonds to unspecified objects in accordance with the authorization of the company’s first extraordinary general meeting in 2021, the requirements of relevant laws and regulations, combined with the actual situation and market conditions of the company. The issuance scheme complies with the requirements of laws, regulations and normative documents such as the company law, the securities law and the measures for the administration of securities issuance and registration of companies listed on the science and Innovation Board (for Trial Implementation). The scheme is reasonable, practical and feasible, in line with the interests of the company and all shareholders, and there is no damage to the interests of the company and its shareholders, especially the minority shareholders.
2. The company’s review procedures comply with the provisions of relevant laws and regulations and the articles of association. There is no situation damaging the interests of the company and other shareholders, especially small and medium-sized shareholders, and it is in the interests of all shareholders.
3. Agree to this proposal. 2、 Deliberating the proposal on the listing of convertible corporate bonds issued by the company to unspecified objects
1. After examination, the company will apply for the listing of convertible corporate bonds on Shanghai Stock Exchange after the issuance of convertible corporate bonds. According to the authorization of the company’s first extraordinary general meeting in 2021, the board of directors of the company authorizes the company’s management and its authorized persons to handle the specific matters of convertible corporate bonds listing.
2. The company’s review procedures comply with the provisions of relevant laws and regulations and the articles of association. There is no situation damaging the interests of the company and other shareholders, especially small and medium-sized shareholders, and it is in the interests of all shareholders.
3. Agree to this proposal. 3、 Deliberation on the proposal on opening a special account for raising funds by issuing convertible corporate bonds to unspecified objects and signing a supervision agreement on raising funds
1. Upon examination, the board of directors of the company authorized the management of the company and its authorized persons to open a special account for the raised funds and sign the supervision agreement for the raised funds, in order to standardize the deposit, use and management of the raised funds and effectively protect the legitimate rights and interests of investors, It complies with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies and the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and there is no situation that damages the interests of the company and its shareholders, especially the minority shareholders.
2. The company’s review procedures comply with the provisions of relevant laws and regulations and the articles of association. There is no situation damaging the interests of the company and other shareholders, especially small and medium-sized shareholders, and it is in the interests of all shareholders.
3. Agree to this proposal. (no text below)
